Proven Clinical Activity in Community-Acquired Bacterial Pneumonia
(CABP) When Caused by the Following Pathogens: |
|
Gram-positive organisms | Gram-negative organisms |
Streptococcus pneumoniae
(including cases with concurrent bacteremia) |
Haemophilus influenzae |
Staphyloccocus aureus
(methicillin-susceptible isolates only)* |
Klebsiella pneumoniae |
Klebsiella oxytoca | |
Escherichia coli |
Proven Clinical Activity in Community-Acquired Bacterial Pneumonia (CABP) When Caused by the Following Pathogens: |
Gram-positive organisms |
Streptococcus pneumoniae (including cases with concurrent bacteremia) |
Staphylococcus aureua (methicillin-susceptible isolates only)* |
Gram-negative organisms |
Haemophilus influenzae |
Klebsiella pneumoniae |
Klebsiella oxytoca |
Escherichia coli |
Clinical efficacy of TEFLARO® in treating CABP due to MRSA has not been studied.
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.